1. Neonatal diabetes mutations disrupt a chromatin pioneering function that activates the human insulin gene.
- Author
-
Akerman I, Maestro MA, De Franco E, Grau V, Flanagan S, García-Hurtado J, Mittler G, Ravassard P, Piemonti L, Ellard S, Hattersley AT, and Ferrer J
- Subjects
- Alleles, Animals, Chromatin chemistry, Chromatin pathology, DNA-Binding Proteins deficiency, Diabetes Mellitus metabolism, Diabetes Mellitus pathology, Embryo, Mammalian, Gene Expression Regulation, Developmental, Humans, Infant, Newborn, Infant, Newborn, Diseases, Insulin deficiency, Mice, Mice, Transgenic, Pancreas growth & development, Pancreas pathology, Promoter Regions, Genetic, Protein Isoforms deficiency, Protein Isoforms genetics, Repressor Proteins deficiency, Trans-Activators deficiency, Transcription, Genetic, Chromatin metabolism, DNA-Binding Proteins genetics, Diabetes Mellitus genetics, Insulin genetics, Pancreas metabolism, Point Mutation, Repressor Proteins genetics, Trans-Activators genetics
- Abstract
Despite the central role of chromosomal context in gene transcription, human noncoding DNA variants are generally studied outside of their genomic location. This limits our understanding of disease-causing regulatory variants. INS promoter mutations cause recessive neonatal diabetes. We show that all INS promoter point mutations in 60 patients disrupt a CC dinucleotide, whereas none affect other elements important for episomal promoter function. To model CC mutations, we humanized an ∼3.1-kb region of the mouse Ins2 gene. This recapitulated developmental chromatin states and cell-specific transcription. A CC mutant allele, however, abrogated active chromatin formation during pancreas development. A search for transcription factors acting through this element revealed that another neonatal diabetes gene product, GLIS3, has a pioneer-like ability to derepress INS chromatin, which is hampered by the CC mutation. Our in vivo analysis, therefore, connects two human genetic defects in an essential mechanism for developmental activation of the INS gene., Competing Interests: Declaration of interests P.R. is a shareholder and consultant for Endocells/Unicercell Biosolutions. The other authors declare no competing interests., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF